多形神経膠芽腫治療（GBM）の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Glioblastoma Multiforme Treatment (GBM) Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D005-00442 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール • 産業分類：医療・製薬

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、多形神経膠芽腫治療（GBM）の世界市場を広く調査・分析し、今後の市場展望をまとめております。多形神経膠芽腫治療（GBM）の種類別市場規模（化学療法、放射線療法、遺伝子療法、分子バイオテクノロジー）、用途別市場規模（ベバコズマブ、カルムスチン、テモゾロミド）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Merck、Sun Pharmaceutical、Teva Pharmaceutical、Arbor Pharmaceuticals、Roche ・地域別グローバル市場分析 2015年-2020年 ・多形神経膠芽腫治療（GBM）の北米市場（アメリカ、カナダ、メキシコ） ・多形神経膠芽腫治療（GBM）のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・多形神経膠芽腫治療（GBM）のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・多形神経膠芽腫治療（GBM）の南米市場（ブラジル、アルゼンチン） ・多形神経膠芽腫治療（GBM）の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：化学療法、放射線療法、遺伝子療法、分子バイオテクノロジー ・用途別分析：ベバコズマブ、カルムスチン、テモゾロミド ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The global Glioblastoma Multiforme Treatment (GBM) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.1% in the forecast period of 2020 to 2025 and will expected to reach USD 755.3 million by 2025, from USD 643.9 million in 2019.

The Glioblastoma Multiforme Treatment (GBM) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Glioblastoma Multiforme Treatment (GBM) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Glioblastoma Multiforme Treatment (GBM) market has been segmented into:
Chemotherapy
Radiotherapy
Gene therapy
Molecular biotechnology

By Application, Glioblastoma Multiforme Treatment (GBM) has been segmented into:
Bevacozumab
Carmustine
Temozolomide

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Glioblastoma Multiforme Treatment (GBM) market presented in the report. This section sheds light on the sales growth of different regional and country-level Glioblastoma Multiforme Treatment (GBM) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Glioblastoma Multiforme Treatment (GBM) market.

The report offers in-depth assessment of the growth and other aspects of the Glioblastoma Multiforme Treatment (GBM) market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Glioblastoma Multiforme Treatment (GBM) Market Share Analysis
Glioblastoma Multiforme Treatment (GBM) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Glioblastoma Multiforme Treatment (GBM) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Glioblastoma Multiforme Treatment (GBM) sales, revenue and market share for each player covered in this report.

The major players covered in Glioblastoma Multiforme Treatment (GBM) are:
Merck
Sun Pharmaceutical
Teva Pharmaceutical
Arbor Pharmaceuticals
Roche

レポート目次

---

Table of Contents

1 Glioblastoma Multiforme Treatment (GBM) Market Overview
1.1 Product Overview and Scope of Glioblastoma Multiforme Treatment (GBM)
1.2 Classification of Glioblastoma Multiforme Treatment (GBM) by Type
1.2.1 Global Glioblastoma Multiforme Treatment (GBM) Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Radiotherapy
1.2.5 Gene therapy
1.2.6 Molecular biotechnology
1.3 Global Glioblastoma Multiforme Treatment (GBM) Market by Application
1.3.1 Overview: Global Glioblastoma Multiforme Treatment (GBM) Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Bevacozumab
1.3.3 Carmustine
1.3.4 Temozolomide
1.4 Global Glioblastoma Multiforme Treatment (GBM) Market by Regions
1.4.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Glioblastoma Multiforme Treatment (GBM) (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Glioblastoma Multiforme Treatment (GBM) Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Glioblastoma Multiforme Treatment (GBM) Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Glioblastoma Multiforme Treatment (GBM) Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Glioblastoma Multiforme Treatment (GBM) Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Glioblastoma Multiforme Treatment (GBM) Status and Prospect (2015-2025)
2 Company Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Merck SWOT Analysis
2.1.4 Merck Product and Services
2.1.5 Merck Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2018-2019)
2.2 Sun Pharmaceutical
2.2.1 Sun Pharmaceutical Details
2.2.2 Sun Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Sun Pharmaceutical SWOT Analysis
2.2.4 Sun Pharmaceutical Product and Services
2.2.5 Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2018-2019)
2.3 Teva Pharmaceutical
2.3.1 Teva Pharmaceutical Details
2.3.2 Teva Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Teva Pharmaceutical SWOT Analysis
2.3.4 Teva Pharmaceutical Product and Services
2.3.5 Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2018-2019)
2.4 Arbor Pharmaceuticals
2.4.1 Arbor Pharmaceuticals Details
2.4.2 Arbor Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Arbor Pharmaceuticals SWOT Analysis
2.4.4 Arbor Pharmaceuticals Product and Services
2.4.5 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2018-2019)
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Roche SWOT Analysis
2.5.4 Roche Product and Services
2.5.5 Roche Glioblastoma Multiforme Treatment (GBM) Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Glioblastoma Multiforme Treatment (GBM) Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Glioblastoma Multiforme Treatment (GBM) Players Market Share
3.2.2 Top 10 Glioblastoma Multiforme Treatment (GBM) Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Glioblastoma Multiforme Treatment (GBM) Revenue and Market Share by Regions
4.2 North America Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
4.3 Europe Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
4.5 South America Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
5 North America Glioblastoma Multiforme Treatment (GBM) Revenue by Countries
5.1 North America Glioblastoma Multiforme Treatment (GBM) Revenue by Countries (2015-2020)
5.2 USA Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
5.3 Canada Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
5.4 Mexico Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
6 Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Countries
6.1 Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Countries (2015-2020)
6.2 Germany Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
6.3 UK Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
6.4 France Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
6.5 Russia Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
6.6 Italy Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Countries
7.1 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Countries (2015-2020)
7.2 China Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
7.3 Japan Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
7.4 Korea Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
7.5 India Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
8 South America Glioblastoma Multiforme Treatment (GBM) Revenue by Countries
8.1 South America Glioblastoma Multiforme Treatment (GBM) Revenue by Countries (2015-2020)
8.2 Brazil Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
8.3 Argentina Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Glioblastoma Multiforme Treatment (GBM) by Countries
9.1 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Countries (2015-2020)
9.2 Saudi Arabia Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
9.3 UAE Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
9.4 Egypt Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
9.5 South Africa Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Glioblastoma Multiforme Treatment (GBM) Revenue and Market Share by Type (2015-2020)
10.2 Global Glioblastoma Multiforme Treatment (GBM) Market Forecast by Type (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Radiotherapy Revenue Growth Rate (2015-2025)
10.5 Gene therapy Revenue Growth Rate (2015-2025)
10.6 Molecular biotechnology Revenue Growth Rate (2015-2025)
11 Global Glioblastoma Multiforme Treatment (GBM) Market Segment by Application
11.1 Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Application (2015-2020)
11.2 Glioblastoma Multiforme Treatment (GBM) Market Forecast by Application (2019-2024)
11.3 Bevacozumab Revenue Growth (2015-2020)
11.4 Carmustine Revenue Growth (2015-2020)
11.5 Temozolomide Revenue Growth (2015-2020)
12 Global Glioblastoma Multiforme Treatment (GBM) Market Size Forecast (2021-2025)
12.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size Forecast (2021-2025)
12.2 Global Glioblastoma Multiforme Treatment (GBM) Market Forecast by Regions (2021-2025)
12.3 North America Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
12.4 Europe Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
12.6 South America Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Glioblastoma Multiforme Treatment (GBM) Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Glioblastoma Multiforme Treatment (GBM) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Glioblastoma Multiforme Treatment (GBM) Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Merck Corporate Information, Location and Competitors
Table 6. Merck Glioblastoma Multiforme Treatment (GBM) Major Business
Table 7. Merck Glioblastoma Multiforme Treatment (GBM) Total Revenue (USD Million) (2017-2018)
Table 8. Merck SWOT Analysis
Table 9. Merck Glioblastoma Multiforme Treatment (GBM) Product and Solutions
Table 10. Merck Glioblastoma Multiforme Treatment (GBM) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Sun Pharmaceutical Corporate Information, Location and Competitors
Table 12. Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Major Business
Table 13. Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Total Revenue (USD Million) (2018-2019)
Table 14. Sun Pharmaceutical SWOT Analysis
Table 15. Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Product and Solutions
Table 16. Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Teva Pharmaceutical Corporate Information, Location and Competitors
Table 18. Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Major Business
Table 19. Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Total Revenue (USD Million) (2017-2018)
Table 20. Teva Pharmaceutical SWOT Analysis
Table 21. Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Product and Solutions
Table 22. Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Arbor Pharmaceuticals Corporate Information, Location and Competitors
Table 24. Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Major Business
Table 25. Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Total Revenue (USD Million) (2017-2018)
Table 26. Arbor Pharmaceuticals SWOT Analysis
Table 27. Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Product and Solutions
Table 28. Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Roche Corporate Information, Location and Competitors
Table 30. Roche Glioblastoma Multiforme Treatment (GBM) Major Business
Table 31. Roche Glioblastoma Multiforme Treatment (GBM) Total Revenue (USD Million) (2017-2018)
Table 32. Roche SWOT Analysis
Table 33. Roche Glioblastoma Multiforme Treatment (GBM) Product and Solutions
Table 34. Roche Glioblastoma Multiforme Treatment (GBM) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Global Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) by Players (2015-2020)
Table 36. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Players (2015-2020)
Table 37. Global Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) by Regions (2015-2020)
Table 38. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Regions (2015-2020)
Table 39. North America Glioblastoma Multiforme Treatment (GBM) Revenue by Countries (2015-2020)
Table 40. North America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries (2015-2020)
Table 41. Europe Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) by Countries (2015-2020)
Table 42. Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) by Countries (2015-2020)
Table 43. South America Glioblastoma Multiforme Treatment (GBM) Revenue by Countries (2015-2020)
Table 44. South America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries (2015-2020)
Table 45. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) by Countries (2015-2020)
Table 46. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries (2015-2020)
Table 47. Global Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) by Type (2015-2020)
Table 48. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Type (2015-2020)
Table 49. Global Glioblastoma Multiforme Treatment (GBM) Revenue Forecast by Type (2021-2025)
Table 50. Global Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2015-2020)
Table 51. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Application (2015-2020)
Table 52. Global Glioblastoma Multiforme Treatment (GBM) Revenue Forecast by Application (2021-2025)
Table 53. Global Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Glioblastoma Multiforme Treatment (GBM) Picture
Figure 2. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type in 2019
Figure 3. Chemotherapy Picture
Figure 4. Radiotherapy Picture
Figure 5. Gene therapy Picture
Figure 6. Molecular biotechnology Picture
Figure 7. Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Application in 2019
Figure 8. Bevacozumab Picture
Figure 9. Carmustine Picture
Figure 10. Temozolomide Picture
Figure 11. Global Glioblastoma Multiforme Treatment (GBM) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Glioblastoma Multiforme Treatment (GBM) Revenue Market Share in 2019
Figure 20. Global Top 10 Players Glioblastoma Multiforme Treatment (GBM) Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Regions (2015-2020)
Figure 24. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Regions in 2018
Figure 25. North America Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 26. Europe Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 28. South America Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 30. North America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries (2015-2020)
Figure 31. North America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries in 2019
Figure 32. USA Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 33. Canada Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 35. Europe Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries in 2019
Figure 37. Germany Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 38. UK Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 39. France Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 40. Russia Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 41. Italy Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries in 2019
Figure 44. China Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 45. Japan Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 46. Korea Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 47. India Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 49. South America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries (2015-2020)
Figure 50. South America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries in 2019
Figure 51. Brazil Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 56. UAE Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Glioblastoma Multiforme Treatment (GBM) Revenue and Growth Rate (2015-2020)
Figure 59. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Type (2015-2020)
Figure 60. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Type in 2019
Figure 61. Global Glioblastoma Multiforme Treatment (GBM) Market Share Forecast by Type (2021-2025)
Figure 62. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 63. Global Radiotherapy Revenue Growth Rate (2015-2020)
Figure 64. Global Gene therapy Revenue Growth Rate (2015-2020)
Figure 65. Global Molecular biotechnology Revenue Growth Rate (2015-2020)
Figure 66. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Application (2015-2020)
Figure 67. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Application in 2019
Figure 68. Global Glioblastoma Multiforme Treatment (GBM) Market Share Forecast by Application (2021-2025)
Figure 69. Global Bevacozumab Revenue Growth Rate (2015-2020)
Figure 70. Global Carmustine Revenue Growth Rate (2015-2020)
Figure 71. Global Temozolomide Revenue Growth Rate (2015-2020)
Figure 72. Global Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Glioblastoma Multiforme Treatment (GBM) Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
Figure 76. Europe Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
Figure 78. South America Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel

---